CNS Drugs

CNS Drugs

1172-7047

1179-1934

Therapeutic Area

Neurology, Pharmacology, Psychiatry

Academics, Anesthesiologists, Caregivers, Clinicians, Geriatricians, Neurologists, Pain Specialists, Patients, Pediatricians, Pharmacologists, Physiatrists, Psychiatrists, Researchers, Substance Abuse Administrators

CNS Drugs promotes rational pharmacotherapy within the disciplines of clinical psychiatry and neurology. The Journal includes: - Overviews of contentious or emerging issues. - Comprehensive narrative reviews that provide an authoritative source of information on pharmacological approaches to managing neurological and psychiatric illnesses. - Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. - Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in neurology and psychiatry. - Original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies. Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in CNS Drugs may be accompanied by plain language summaries to assist readers in understanding important medical advances. All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication. "CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders. Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations. The journal Also offers the ability to create digital features as well as host them.

No associations affiliated with this journal

Adis, part of Springer Nature

Impact Factor JCR Categories/Rank Electronic Circulation Submission to Acceptance Acceptance to Online Publication Acceptance to Print Publication Rejection Rate Frequency Journal Contact Author Submission Guidelines